Korea Exchange · Healthcare
Ilyang Pharmaceutical stock from India: price, numbers and tax
Ilyang Pharmaceutical (007570) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Ilyang Pharmaceutical at a glance
- Price
- ₩7,950.00-₩150.00 (1.85%)
- Market cap
- ₩142.50B
- Day range
- ₩7,910.00 – ₩8,100.00
- P/E
- 7.86
- Dividend yield
- 1.95%
- Volume
- 23.85K
- 1 month
- -3.75%
- 6 months
- -34.57%
- YTD
- -39.08%
- 1 year
- -39.08%
- 5 years
- -74.19%
Ilyang Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩272.2B | ₩268.9B | ₩370.5B | ₩383.8B | ₩371.3B |
| Gross profit | ₩116.4B | ₩111.5B | ₩200.1B | ₩216.0B | ₩204.4B |
| Operating income | ₩5.0B | ₩11.0B | ₩24.8B | ₩40.4B | ₩41.0B |
| Net income | ₩6.9B | ₩10.3B | −₩2.5B | ₩19.4B | ₩14.0B |
| Earnings per share | ₩375.42 | ₩557.00 | −₩139.10 | ₩1,045.00 | ₩771.00 |
| EBITDA | ₩13.3B | ₩25.0B | ₩15.1B | ₩55.6B | ₩52.2B |
| Total assets | ₩468.7B | ₩431.2B | ₩392.6B | ₩498.2B | ₩494.3B |
| Total debt | ₩126.8B | ₩107.7B | ₩84.8B | ₩85.7B | ₩102.1B |
| Cash and short-term investments | ₩29.6B | ₩12.8B | ₩18.9B | ₩12.6B | ₩43.6B |
| Shareholders' equity | ₩237.6B | ₩238.0B | ₩227.0B | ₩234.7B | ₩224.1B |
| Operating cash flow | ₩12.0B | ₩5.6B | ₩19.4B | ₩29.9B | ₩67.0B |
| Free cash flow | ₩1.6B | −₩35.0B | ₩7.4B | ₩9.4B | ₩45.7B |
| Capital expenditure | −₩10.4B | −₩40.6B | −₩12.0B | −₩20.5B | −₩21.4B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Kwang Dong Pharmaceutical | 009290.KS | ₩6,920.00 | ₩343.65B |
| JW | 096760.KS | ₩4,105.00 | ₩284.03B |
| Samjin Pharmaceuticals | 005500.KS | ₩20,100.00 | ₩254.42B |
| REYON Pharmaceutical | 102460.KS | ₩10,280.00 | ₩188.55B |
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| Chong Kun Dang | 001630.KS | ₩37,250.00 | ₩177.33B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
| Jeil Pharmaceutical | 271980.KS | ₩10,050.00 | ₩147.78B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Ilyang Pharmaceutical from India
What Ilyang Pharmaceutical does
Headquartered in Yongin, South Korea, Ilyang Pharmaceutical Co.,Ltd is a prominent pharmaceutical enterprise that has been operating since its establishment in 1946. The company, which was formerly known as Il-Yang Pharm. Ilyang Pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Ilyang Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.